By Jennifer Rigby LONDON (Reuters) -Swiss drugmaker Novartis will keep making medicines for malaria and leprosy, even if it ...

Roche is among several drugmakers to announce large-scale U.S. investments in response to Trump's push to onshore ...

Incyte said it agreed to pay Novartis $280 million to settle the disputed royalties on U.S. sales of blood-cancer treatment Jakafi through Dec. 31. The parties also agreed to reduce by 50% the royalty ...

GSK is acquiring an experimental medicine from a Cambridge biotech to shore up its drug pipeline and muscle into the ...

PTC Therapeutics reported a phase 2 win for its Novartis-partne | PTC Therapeutics reported a phase 2 win for its ...

Just before the May 5 trial date set for Novartis and Incyte to finally hash out their Jakafi royalty dispute in court, the ...

Swiss pharmaceutical giant Novartis is poised to expand its profile in the San Diego area, announcing plans to acquire ...

At the intersection of radiation and precision, Novartis, Bayer, AstraZeneca and more hope to cash in on a ...

After announcing successful trial results for its lead mRNA treatment earlier this year, Regulus Therapeutics agreed to be ...

LONDON, May 12 (Reuters) - Swiss drugmaker Novartis (NOVN.S), opens new tab will keep making medicines for malaria and leprosy, even if it does not get orders as normal amid the global health ...